rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lexaria Bioscience Corp.

LEXX · Nasdaq

Health CareBiotechnologyNot moving yet

LEXX stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 64.2% below that average now. Biotechnology: 17% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 27% (−6 points in four weeks).

Statistics

Last close, 22 Oct 2026
2.99 +6.03%
52-week range
—
Volume
0.02M
Average volume (50 days)
—
Relative volume
—
Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
17% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
29 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

24 Apr – 23 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Price and volume

$2.57$3.28$3.9911 Sep23 Sep2 Oct13 Oct22 Oct
close

Daily bars to 22 Oct 2026: 29 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$114KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders29+2 on the quarter
New · exited5 · 3
Reported value$873K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Invenomic Capital Management LPreduced · filed 14 Aug 2026345,685$194K-96,616−21.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026298,436$167K+76,143+34.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026250,415$140K-43,742−14.9%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026156,945$88K+143,432+1061.4%
TORONTO DOMINION BANKreduced · filed 14 Aug 2026100,013$56K-40,000−28.6%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202694,166$53K00.0%
UBS Group AGreduced · filed 13 Aug 202646,966$26K-5,742−10.9%
NORTHERN TRUST CORPadded · filed 13 Aug 202639,825$22K+21,436+116.6%
STATE STREET CORPunchanged · filed 7 Aug 202639,301$22K00.0%
BlackRock, Inc.unchanged · filed 7 Aug 202627,445$15K00.0%
31 Mar 2023 – 30 Jun 2026
122028Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Christopher Bunka Company insiderDirector · last 17 Mar 2026339 · 0
John Martin Docherty Company insiderPresident & CSO · last 29 Jul 20255 · 0
Richard Christopher Company insiderChief Executive Officer · last 29 Jul 20253 · 0
Vanessa Carle Company insiderSecretary · last 29 Jul 20251 · 1
William Edward McKechnie Company insiderDirector · last 29 Jul 20252 · 2
Albert L. Reese, Jr. Company insiderDirector · last 15 May 20250 · 0
Baljinder Bhullar Company insiderDirector · last 15 May 20252 · 0
Michael Elliot Shankman Company insiderChief Financial Officer · last 15 May 20250 · 0
Nicholas W. Baxter Company insiderDirector · last 15 May 20252 · 0
Catherine C. Turkel Company insiderDirector · last 12 Aug 20242 · 0
Gregory Downey Company insiderChief Financial Officer · last 14 Oct 20221 · 0
Allan Horst Spissinger Company insiderChief Financial Officer · last 23 Apr 20200 · 0

Same industry

MRNA ModernaLeading+113%
ENTX Entera BioLeading+45%
XNCR XencorLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Aug 202599.6%
Share count trendFY 2025 · to 25 Nov 202513.6%
Cash and equivalentsFY 2025 · to 31 Aug 2025$1.8M
Free cash flowFY 2025 · to 31 Aug 2025−$10.5M

Analyst forecasts

No analyst forecasts yet.